Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431610 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis
A Phase 1 study, sponsored by Novan.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03431610 is a Phase 1 study that has completed, run by Novan. The registered enrollment target is 48 participants.
The verdict
NCT03431610, a Phase 1 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1b, 2-week study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of SB414 in subjects with mild to moderate AD.
Interventions
- DRUG Vehicle
- DRUG SB414 2%
- DRUG SB414 6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2018-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03431610
The ClinicalTrials.gov registry entry for NCT03431610 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT03431610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03431610 about?
NCT03431610 is a clinical study titled "A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis". This is a Phase 1b, 2-week study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of SB414 in subjects with mild to moderate AD.
What is the current status of trial NCT03431610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-11-13. Estimated completion is 2018-05-11.
What interventions are being tested in trial NCT03431610?
The interventions under investigation include: Vehicle (DRUG), SB414 2% (DRUG), SB414 6% (DRUG).
Who is sponsoring clinical trial NCT03431610?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.